AstraZeneca "incredibly excited" by lung cancer treatment trial13 Apr 2020
Independent Data Monitoring Committee (IDMC) recommends unblind Phase III trial of Tagrisso 2 years ahead of schedule.
AstraZeneca has cause for celebration after the Phase III trial for Tagrisso (osimertinib) in the adjuvant treatment of postsurgery patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) will be unblinded early following a recommendation from an IDMC based on its determination of overwhelming efficacy.
In a Phase III trial named ADAURA, Tagrisso was pitted against placebo for a treatment duration of up to 3 years, during which investigators measured disease-free survival (DFS).
José Baselga, AstraZeneca's Executive Vice President, Oncology R&D said they were "incredibly excited with the unprecedented results" in patients with early-stage EGFRm NSCLC.
The trial will continue to assess the secondary endpoint of overall survival.
In its communication to AstraZeneca, the IDMC did not raise any new safety concerns.
José Baselga said: "We are thrilled by the recommendation to unblind the Phase III ADAURA trial much earlier than expected. Lung cancer is a devastating diagnosis and for the first time an EGFR-targeted medicine can now provide the hope of cure."
The company has said it will present the data at a forthcoming medical meeting.
HKBU scientists develop technique to eliminate drug side effects
19 May 2020
The novel method paves the way towards the mass production of affordable therapeutic drugs that are made with recyclable materials.Read more
Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit
18 May 2020
CDMO is contracted to produce multiple clinical batches from German facilityRead more
Characterizing virus and virus-like particles
12 May 2020
New application study describes the separation and characterisation of adeno associated virus serotypes by AF4.Read more
AI technology company launches with Novartis and Sarepta deals
11 May 2020
Collaborations focus on gene therapies for serious eye and muscle diseases using Dyno’s CapsidMap artificial intelligence platform to design AAV vectors.Read more
Bio-Rad launches anti-certolizumab pegol antibodies
5 May 2020
Using this critical antibody reagent at the preclinical stage of development will minimize the need to revalidate assays with different reagents at the clinical development stage.Read more
BERG named visionary in first-ever Frost Radar AI in Drug Discovery report
13 Apr 2020
The biotech pioneer is one of the first companies to develop corporate partnerships in this application of artificial intelligence (AI) for drug discovery.Read more
German pharma companies are meeting the corona "stress test"
7 Apr 2020
The head of the leading German pharmaceutical industry organization says German firms are working top-speed to find coronavirus medications.Read more
World’s leading biobanks join a global network to advance personalized healthcare research
6 Apr 2020
The platform enables collaboration between pharmaceutical institutions, healthcare and academic researchers to generate valuable insights and advance medical research.Read more
Servier strengthens its R&D pipeline with Symphogen acquisition
6 Apr 2020
Symphogen becomes the antibody center of excellence within Servier.Read more
Evotec expands into gene therapy with new Austrian unit
6 Apr 2020
Evotec has established a dedicated gene therapy-based R&D site in Orth an der Donau, Austria with the immediate focus of spearheading a partnership with Japan’s Takeda to support its research projects, the German drug discovery firm said Monday.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation